GlobeImmune, Inc.
GBIM
$0.0002
$0.000.00%
OTC PK
| 03/31/2016 | 12/31/2015 | 09/30/2015 | 06/30/2015 | 03/31/2015 | |
|---|---|---|---|---|---|
| Revenue | -20.63% | -30.63% | 125.44% | -26.23% | -16.25% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -20.63% | -30.63% | 125.44% | -26.23% | -16.25% |
| Cost of Revenue | -52.47% | -80.83% | -55.61% | -49.94% | 11.89% |
| Gross Profit | 307.62% | 175.90% | 1,182,450.00% | 130.14% | -76.70% |
| SG&A Expenses | -21.79% | -10.76% | -7.58% | 38.03% | 17.62% |
| Depreciation & Amortization | -75.82% | -74.64% | -73.24% | -4.48% | 13.02% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.33% | -40.26% | -31.36% | -15.82% | 4.77% |
| Operating Income | 44.75% | 48.61% | 164.67% | 2.35% | -29.51% |
| Income Before Tax | 44.75% | 54.35% | 114.05% | 77.16% | 36.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 44.75% | 54.35% | 114.05% | 77.16% | 36.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.75% | 54.35% | 114.05% | 77.16% | 36.17% |
| EBIT | 44.75% | 48.61% | 164.67% | 2.35% | -29.51% |
| EBITDA | 43.09% | 47.39% | 169.47% | 2.23% | -30.52% |
| EPS Basic | 44.75% | 54.13% | 113.13% | 99.76% | 99.57% |
| Normalized Basic EPS | 44.75% | 48.33% | 158.10% | 99.61% | 98.97% |
| EPS Diluted | 44.75% | 53.25% | 110.98% | 99.76% | 99.57% |
| Normalized Diluted EPS | 44.75% | 48.33% | 148.09% | 99.61% | 98.97% |
| Average Basic Shares Outstanding | 0.00% | -0.50% | 2.23% | 5,763.00% | 6,071.24% |
| Average Diluted Shares Outstanding | 0.00% | -0.50% | 23.47% | 5,763.00% | 6,071.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |